Search

Author/Creator Ramos, Aura Y.

1. A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia. Issue 6 (20th December 2019)

Authors:
Narayan, Rupa; Blonquist, Traci M.; Emadi, Ashkan; Hasserjian, Robert P.; Burke, Meghan; Lescinskas, Christopher; Neuberg, Donna S.; Brunner, Andrew M.; Hobbs, Gabriela; Hock, Hanno; McAfee, Steven L.; Chen, Yi‐Bin; Attar, Eyal; Graubert, Timothy A.; Bertoli, Christina; Moran, Jenna A.; Bergeron,...
Journal:
Cancer
Issue:
Volume 126:Issue 6(2020)
Page Start:
1264
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation. Issue 2 (28th September 2017)

Authors:
Fathi, Amir T.; Blonquist, Traci M.; Hernandez, Daniela; Amrein, Philip C.; Ballen, Karen K.; McMasters, Malgorzata; Avigan, David E.; Joyce, Robin; Logan, Emma K.; Hobbs, Gabriela; Brunner, Andrew M.; Joseph, Christelle; Perry, Ashley M.; Burke, Meghan; Behnan, Tanya; Foster, Julia; Bergeron, Me...
Journal:
Cancer
Issue:
Volume 124:Issue 2(2018)
Page Start:
306
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search